eyestock logo

eyestock

SC

Scorpius Holdings IncNYSE-MKT SCPX

Последний отчетный период 31 мар., 2024

Обновлено 12 нояб., 2024

Последняя цена

Капитализация млрд. $

0.003

Micro

Биржа

XASE - Nyse MKT LLC

Анализ акций SCPX

SC

Нет оценки

Количественный анализ Eyestock не покрывает акции Scorpius Holdings Inc.

Рейтинг

Для оценки качества бизнеса компании мы собрали все финансовые данные из отчетов и представили их в виде одного числа - рейтинга компании. Значение рейтинга 100 является пороговым для определения актуальной инвестиционной идеи.

-33/100

Низкий рейтинг

Капитализация млрд. $

0.003

Дивидендная доходность

Оборот

96.66 млрд

Сайт компании

https://www.nighthawkbio.com/

Scorpius Holdings, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company is headquartered in Morrisville, North Carolina and currently employs 82 full-time employees. The company went IPO on 2013-07-24. The firm is focused on advancing biologic and cell therapy programs to the clinic and beyond. The company offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas. Its analytical services include development of a comprehensive range of analytical test methods to characterize complex biologics, including cell therapy-based products, protein therapeutics, vaccines and advanced therapies. Its Clinical Biomanufacturing includes cGMP Mammalian Cell Culture, and cGMP Microbial Fermentation. Its San Antonio facility is focused on the commercial-scale manufacturing of biodefense-focused molecules and biologics therapeutics. Its biomanufacturing services focus on accelerating product development timelines from pre-clinical evaluation to first-in-human studies.

Смотреть Секцию: Рейтинг